SOCM
SR One Capital Management Portfolio holdings
AUM
$706M
1-Year Est. Return
112.64%
This Fund
S&P 500
1 Year Est. Return
+112.64%
AUM
$706M
AUM Growth
+$15M
(+2.2%)
Holding
13
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ZBIO
1
Zenas BioPharma
ZBIO
$1.1B
| $183M | 25.9% |
5,037,854
+126,315
|
|
||
2
Arcellx
ACLX
$6.7B
| $153M | 21.66% |
2,346,630
|
|
||
3
CRISPR Therapeutics
CRSP
$4.52B
| $107M | 15.14% |
2,038,763
|
|
||
4
Design Therapeutics
DSGN
$627M
| $61.2M | 8.67% |
6,526,476
|
|
||
5
Mineralys Therapeutics
MLYS
$1.97B
| $56.8M | 8.03% |
1,563,966
-549,967
|
|
||
6
ARS Pharmaceuticals
SPRY
$758M
| $46.8M | 6.62% |
4,012,903
|
|
||
7
Oric Pharmaceuticals
ORIC
$1.26B
| $37.8M | 5.34% |
4,514,929
|
|
||
|
ALMS
8
Alumis Inc
ALMS
$2.91B
| $19.1M | 2.71% |
1,959,896
|
|
||
|
ORKA
9
Oruka Therapeutics
ORKA
$2.04B
| $13M | 1.85% |
430,330
|
|
||
10
Oculis Holding
OCS
$1.44B
| $12.8M | 1.81% |
641,022
+318,522
|
|
||
11
enGene Holdings
ENGN
$498M
| $6.75M | 0.96% |
747,750
|
|
||
12
Nkarta
NKTX
$156M
| $6.17M | 0.87% |
3,333,333
|
|
||
13
Ultragenyx Pharmaceutical
RARE
$1.95B
| $3.17M | 0.45% |
+137,753
|
|